EUVIMEDEUVIMED entdecken
Klinische Studie

Methylglyoxal-Induced Glycation of Plasma Albumin: From Biomarker Discovery to Clinical Use for Prediction of New-Onset Diabetes in Individuals with Prediabetes

Arsênio Rodrigues Oliveira, Chloé Chevalier, Matthieu Wargny iD, Victoria Pakulska, Cédric Caradeuc, Chloé Cloteau, Marine P M Letertre, Nicolas Giraud, Gildas Bertho, Edith Bigot-Corbel, Maxime Carpentier, Georges Nouadje und 5 weitere

Clinical Chemistry · 2025

DOI: 10.1093/clinchem/hvaf035 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Arsênio Rodrigues Oliveira und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France. Hauptthemen laut MEDLINE: Diabetes Mellitus, Diabetes Mellitus, Type 2, Prediabetic State, Pyruvaldehyde. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: DGOS, Agence Nationale de la Recherche, Graduate School.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methylglyoxal (MGO) is a potent glycating agent that contributes to the pathogenesis of diabetes. However, MGO is unstable in plasma without demanding sample preparation at blood collection, limiting its clinical utility as a biomarker. We aimed to discover reliable MGO-glycated albumin (ALB)-derived biomarkers and to assess their association with new-onset diabetes (NOD) in people with prediabetes.

Methods

Bottom-up mass spectrometry-based proteomics was used to discover peptide biomarkers of MGO-glycated ALB, including MGO-derived hydroimidazolone (MGH)-ALB219–225, which proved to be biologically stable and reliable for large-scale analyses in human plasma. After assay validation, the IT-DIAB (Innovation Thérapeutique DIABète) prospective study, conducted in 300 individuals with impaired fasting plasma glucose (FPG) levels (110 to 125 mg/dL, 6.1 to 6.9 mmol/L), was used to assess the association between plasma MGH-ALB219–225 and NOD, defined as FPG ≥126 mg/dL (7 mmol/L), using Kaplan–Meier curves and Cox models.

Results

In total, 113 participants of the IT-DIAB study developed NOD during a median follow-up of 5 years. There was a graded association between the baseline plasma MGH-ALB219–225 concentration and incident NOD (log-rank P < 0.0001), in contrast to a lack of association for plasma MGO and total or glycated ALB (commercial kit). After adjustment for age, sex, body mass index, FPG, hemoglobin (Hb) A1c, and ALB, the plasma levels of MGH-ALB219–225 were associated with NOD (hazard ratio [HR] per one SD [95% CI] = 1.50 [1.26–1.78]; P < 0.0001).

Conclusions

MGH-ALB219–225 is a novel and stable peptide biomarker of MGO-glycated ALB, whose plasma levels are positively associated with an increased risk of NOD in individuals with prediabetes, independently of traditional risk factors. ClinicalTrials.gov Registration Number: NCT01218061

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusDiabetes Mellitus, Type 2Prediabetic StatePyruvaldehydeSerum AlbuminAdultAgedFemaleHumansMaleMiddle AgedBiomarkersGlycated Serum AlbuminGlycation End Products, AdvancedGlycosylationMass SpectrometryProspective Studies

Substanzen

BiomarkersGlycated Serum AlbuminGlycation End Products, AdvancedPyruvaldehydeSerum Albumin

Autor:innen und Institutionen

  • Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
  • New Biomarkers Department, Sebia, Evry, France.
  • CHU de Nantes, INSERM CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, Nantes, France.
  • Université Grenoble Alpes, CEA, INSERM, UA13 BGE, CNRS, CEA, FR2048, Grenoble, France.
  • Université Paris Cité, CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Paris, France.
  • MetaboParis-Santé, BioMedTech Facilities-Inserm US36, CNRS UAR2009, Université Paris Cité, Paris, France.

ORCID-Profile: Matthieu Wargny, Yohann Couté, Mikaël Croyal

Förderung

  • DGOS
  • Agence Nationale de la Recherche
  • Graduate School

Zitieren

APA

Rodrigues Oliveira, A., Chevalier, C., Wargny, M., Pakulska, V., Caradeuc, C., Cloteau, C., Letertre, M. P. M., Giraud, N., Bertho, G., Bigot-Corbel, E., Carpentier, M., Nouadje, G., Couté, Y., Le May, C., Cariou, B., Hadjadj, S., & Croyal, M. (2025). Methylglyoxal-Induced Glycation of Plasma Albumin: From Biomarker Discovery to Clinical Use for Prediction of New-Onset Diabetes in Individuals with Prediabetes. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvaf035

Vancouver

Rodrigues Oliveira A, Chevalier C, Wargny M, Pakulska V, Caradeuc C, Cloteau C, et al. Methylglyoxal-Induced Glycation of Plasma Albumin: From Biomarker Discovery to Clinical Use for Prediction of New-Onset Diabetes in Individuals with Prediabetes. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvaf035

BibTeX
@article{RodriguesOliveira2025,
  author = {Rodrigues Oliveira, Arsênio and Chevalier, Chloé and Wargny, Matthieu and Pakulska, Victoria and Caradeuc, Cédric and Cloteau, Chloé and Letertre, Marine P M and Giraud, Nicolas and Bertho, Gildas and Bigot-Corbel, Edith and Carpentier, Maxime and Nouadje, Georges and Couté, Yohann and Le May, Cédric and Cariou, Bertrand and Hadjadj, Samy and Croyal, Mikaël},
  title = {Methylglyoxal-Induced Glycation of Plasma Albumin: From Biomarker Discovery to Clinical Use for Prediction of New-Onset Diabetes in Individuals with Prediabetes},
  journal = {Clinical Chemistry},
  year = {2025},
  doi = {10.1093/clinchem/hvaf035}
}
Kostenlos starten →